Sign in Subscribe
Cancer cells

Breakthrough in Ovarian Cancer Treatment: New Research Highlights Potential of PARP Inhibitors

Strategic Insights

— 1 min read

A team of researchers at the University of Bonn has made a groundbreaking discovery in the field of ovarian cancer treatment. In a study published in Cell Death Discovery, the researchers investigated the efficacy of PARP inhibitors in treating ovarian cancer cells that are resistant to cisplatin, a commonly used chemotherapy drug. The study found that the combination of PARP inhibitors with inhibitors of relevant DNA damage response kinases, such as ATR and ATM, increased the activity of PARP inhibitors against both cisplatin-sensitive and -resistant ovarian cancer cells.

Key Takeaways:

  • The study revealed complex, cell line-specific response profiles to PARP inhibitors, which are in line with other studies investigating drug-resistant cancer cell lines.
  • Cisplatin resistance was not directly correlated with PARPi resistance, and ATM and ATR inhibitors can increase PARPi activity against cisplatin-sensitive and -resistant ovarian cancer cells.
  • The study demonstrated for the first time that cell adhesion-mediated resistance can contribute to PARPi resistance, which can also be alleviated by ATR and ATM.
  • The research has significant implications for the treatment of ovarian cancer, particularly in cases where cancer cells have developed resistance to cisplatin.
  • The study highlights the potential of combining PARP inhibitors with other inhibitors of DNA damage response kinases to improve treatment outcomes.

Statistics:

  • 3 approved PARP inhibitors, niraparib, olaparib, and rucaparib, were tested in the study.
  • The study involved 3 ovarian cancer cell lines and their cisplatin-resistant sublines.
  • The combination of PARP inhibitors with ATR and ATM inhibitors resulted in increased PARPi activity against cisplatin-sensitive and -resistant ovarian cancer cells.
  • The study found that collagen I can mediate PARPi resistance, which can be tackled by ATR and ATM inhibition.

Sources:

  • "Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition." Cell Death Discovery, 2025;11(1):438.
  • Springernature, Campus, 4 Crinan St, London, N1 9XW, England.

Read more